TOPIC

Best of the Year 2024

MODERATORS

Hope Rugo, MD, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, Medical Director of Cancer Infusion Services, UCSF Helen DIller Family Comprehensive Cancer Center

Laura Crocitto, MD, Vice President and Chief Medical Officer for Cancer Services, Medical Director, UCSF Helen Diller Family Comprehensive Cancer Center

-------

PRESENTATIONS

"Best of the year: Breast Oncology"

Tiffany Svahn, MD, President, John Muir Health Cancer Medical Group Susan Desmond-Hellmann Medical Director of Oncology UCSF-John Muir Health Jean and Ken Hofmann Cancer Center

After completing this course, attendees will have improved their skills and strategies for:

• Understanding the role of adjuvant CDK 4/6 inhibitors in high-risk earlystage hormone receptor-positive breast cancer
• Understanding the role of neoadjuvant/adjuvant immunotherapy for stage II/III triple-negative breast cancer
• Understanding the use of antibody-drug conjugates for the treatment of HR positive/HER2 negative metastatic breast cancer

-------

"Best of the year: Lung Oncology"

Claire Mulvey, MD, Assistant Professor of Thoracic Oncology University of California, San Francisco

Gigi Chen, MD, Medical Director, Oncology Research John Muir Health Cancer Medical Group

After completing this course, attendees will have improved their skills and should be able to:

• Understand advances in targeted therapy for stage IV non-small cell lung cancer
• Practice changing results in management of stage III EGFR mutated non-small cell lung cancer
• Summarize the role of immunotherapy in limited stage small cell lung cancer
• Discuss the role of tarlatamab in extensive stage small cell lung cancer and other potential T cell engagers on the horizon

-------

"Best of the year: Genitourinary (GU) Oncology"

Ivan de Kouchkovsky, MD, Assistant Professor Hematology & Oncology Department of Medicine University of California, San Francisco

Dr. Tianyi Tang, MD, PhD, Hematology/Medical Oncology John Muir Health Cancer Medical Group

After completing this course, attendees will have improved their skills and strategies for:

• The management of patients with high-risk biochemically recurrent prostate cancer
• The use of PSMA radioligand therapy in chemotherapy-naive prostate cancer patients
• The use of adjuvant therapy in high-risk muscle invasive bladder cancer
• The treatment of patients with HER2 positive metastatic urothelial carcinoma

-------

"Best of the year: Gastrointestinal Oncology"

Travis Zack, MD, PhD, Assistant Professor GI Medical Oncology UCSF Helen Diller Family Comprehensive Cancer Center

Dr. Ronak Patel, MD, Hematology/Medical Oncology John Muir Health Cancer Medical Group

After completing this course, attendees will have improved their skills and strategies for:

• Management of localized esophageal cancer using recent ESOPEC data
• Real-world application and outcomes of adjuvant immunotherapy for esophageal cancer
• Immunotherapy in pancreatic cancer based on what we've tried and what is on the horizon
• Optimizing the treatment course in settings with few options and frequently poor response

-------

REGISTRATION

To secure your spot, please register in advance. 

• REGISTER WITH CME
• REGISTER WITHOUT CME